Abstract
Idiopathic aplastic anemia (IAA) is a rare autoimmune bone marrow failure disorder initiated by a human leukocyte antigen (HLA)-restricted T-cell response to unknown antigens. Immunogenetic patterns associated with self-antigenic presentation remain unclear. Herein we analyzed the molecular landscape of HLA complexes and T-cell receptor (TCR) repertoires of a large cohort of IAA patients and controls. We show that antigen binding sites of class II HLA molecules in IAA are characterized by a high level of structural homology, only partially explained by specific risk allele profiles, implying reduced binding capabilities compared to controls. Few amino acids within the synapsis HLA-DRB1-antigen-TCR, are identified as strongly associated with IAA phenotype. Those structural patterns may affect TCR repertoires, promoting immunological cross-reactivity and autoimmunity. These findings inform on the immunogenetic risk associated with IAA and on general pathophysiological mechanisms potentially involved in autoimmunity.
Key points
Class II human leukocyte antigen (HLA) loci in idiopathic bone marrow failure (BMF) syndromes are characterized by low functional divergence and decreased peptide binding capabilities, only partially explained by enrichment in risk alleles.
A superstructure at the interface with the peptide binding site of DRB1 locus, potentially involved in the presentation of self-antigenic specificities, can be identified in BMF patients.
This immunogenetic pattern may contribute to decrease T-cell receptor repertoire diversity, expand autoreactive T-cell clones and increase autoimmune propensity in BMF.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by US National Institute of Health (NIH) grants R35 HL135795, R01HL123904, R01 380HL118281, R01 HL128425, R01 HL132071, Edward P.Evans Foundation (to J.M), Italian Society of Hematology, Fondation ARC pour la Recherche sur le Cancer, Philippe Foundation, Association HPN France/Fondation de maladies rares (to S.P.); The American Italian Cancer Foundation (to C.G.); VeloSano Pilot Award, and Vera and Joseph Dresner Foundation MDS (to V.V.); The European Research Council (M IMM and STRATIFY projects), Academy of Finland, Sigrid Juselius Foundation, and Cancer Foundation Finland (to S.L. and S.M). We thank Diego Chowell for his helpful insights and critical revision of the manuscript. We thank the National Institute of Diabetes and Digestive and Kidney diseases and the Type 1 Diabetes Genetic Consortium that provided the T1DGC Immunochip/HLA Reference Panel used in this study. We thank Dr. John Sidney and Prof. Alessandro Sette who kindly provided the ethnicity and race information for the subjects from San Diego population.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was conducted under the institutional review board of Cleveland Clinic (IRB #5024)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All the data that support the findings of this study are available within the Article and Supplementary Files. Genotypic and phenotypic raw data, including HLA genotypes of all the subject in study will be provided upon request to the corresponding authors. TCR sequencing data will be provided through the ImmuneACCESS platform (Adaptive Biotechnology).
